News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Sahm Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
J. Goldman & Co LP has acquired a new stake in MiniMed Group Inc (NASDAQ:MMED), purchasing over 830,000 shares valued at approximately $12.41 million during the second quarter. Other institutional investors, including Bank of New York Mellon Corp and BlackRock Inc., have also recently โฆ
MiniMed Group Inc.'s lock-up period for insiders and major shareholders is set to expire on September 2nd, allowing them to sell shares. The company's IPO issued 28 million shares at $20 each. Despite a recent stock decline and missed earnings estimates, analyst sentiment remains โฆ
This article reports on an SEC filing (Form ARS) by MiniMed Group, Inc. (MMED) on August 21, 2026. The filing was accepted by the SEC EDGAR system at 04:24 PM EST. The article provides company stock data, recent news, and other SEC filings for โฆ
Two healthcare innovators, MiniMed Group, Inc. (NASDAQ:MMED) and Abbott Laboratories (NYSE:ABT), hit the spotlight this August with a milestone partnership. On August 17, MiniMed announced that its MiniMed Flex system is commercially shipping in the U.S., integrated with Abbott's Instinct continuous glucose sensor. This โฆ
MiniMed Group, Inc. MMED recently announced that the MiniMed Flex system is now commercially shipping in the United States with Abbott Laboratories' Instinct sensor. The combination brings together the company's smallest and only app-controlled insulin pump with a sensor offering up to 15 days โฆ
MiniMed has commercially launched its MiniMed 780G and MiniMed Go automated insulin delivery systems integrated with Abbott Laboratories' Instinct and Instinct Go sensors across European markets. This expansion provides greater flexibility and choice for people with diabetes, enhancing MiniMed's competitive position in the growing โฆ
MiniMed Inc. announced the commercial shipment of its MiniMed Flex system in the United States, featuring the Instinct sensor from Abbott Laboratories. This system offers individuals with diabetes an app-controlled insulin pump combined with the world's smallest sensor, providing up to 15 days of โฆ
MiniMed Flexโข with Instinct, made by Abbott, combines discreet design, up to 15 days of sensor wear and proven automation to reduce the work and interruptions of diabetes management NORTHRIDGE, Calif., Aug. 17, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) today announced that the MiniMed โฆ
This article provides live quotes and charts for MiniMed Group Inc. (MMED) stock, showing its current price as $20.15 with no change. It also indicates that there is no analyst rating data or earnings information currently available for the company. The page promotes a โฆ
DexCom, Inc. DXCM is entering the second half of 2026 with healthier margins, broader reimbursement and a larger continuous glucose monitoring opportunity. The investment question is whether that improving setup is enough to justify a premium valuation. Growth catalysts remain visible across U.S. coverage, โฆ
DexCom, Inc. DXCM shares have climbed 52.5% in the past three months, a sharp re-rating that raises the standard for further gains. The next leg depends less on momentum alone and more on whether earnings growth, margin expansion and new-market access can keep pace โฆ
MiniMed, recently spun out from Medtronic, is focusing on innovation in diabetes device technology. The company, a leader in durable, tubed insulin pumps for Type 1 diabetes, faces increasing competition despite its historical market presence. An analyst note initiates coverage with a "no-moat" rating โฆ
This stock analysis report for MiniMed Group (Nasdaq:MMED) provides an overview of the company's financial health, future growth prospects, past performance, and valuation. It highlights recent news including the launch of new insulin pump systems, board changes, and financial results, noting the company is โฆ
BofA Securities has raised its price target for MiniMed Group (MMED) shares to $24 from $20. This adjustment follows UBS initiating coverage on MiniMed Group with a Buy rating and a $25 price target on July 29th. MiniMed Group, a medical technology company specializing โฆ
BofA Securities has raised its price target for MiniMed Group (NASDAQ: MMED) shares to $24 from $20, while maintaining a Buy rating. The increase is attributed to the approaching potential window for Medtronic to exchange its 90% ownership in MiniMed Group for Medtronic shares. โฆ
MiniMed Group (NASDAQ: MMED) announced that its Senior Vice President, General Counsel, and Corporate Secretary, Courtney Nelson Wills, will resign effective September 25, 2026. Ms. Wills notified the company on July 30, 2026, and her departure is due to personal reasons, as she has โฆ
Analysts have given MiniMed Group Inc (NASDAQ:MMED) a "Moderate Buy" consensus recommendation, with 13 buy ratings, two holds, and one sell from 16 firms. The average 12-month price target is $21.62, higher than the stock's opening price of $18.05. Despite mixed recent analyst actions โฆ
MiniMed Group, Inc. (MMED) announced that its MiniMed Flex system, an app-controlled insulin pump, is now covered by Medicare and Medicare Advantage in the U.S., expanding access for diabetes patients. This move is expected to bolster MMED's market presence and revenue opportunities by increasing โฆ
MiniMed Group, Inc. (NASDAQ: MMED) generated $3.10 billion USD in total revenue last year. Its top-performing segment, Continuous Glucose Monitoring, contributed $1.55 billion USD. The "Rest of World" region was the largest contributor to revenue, accounting for $2.19 billion USD.
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States